Mostrar el registro sencillo del ítem

dc.contributor.authorDiebold Luque, María Yolanda 
dc.contributor.authorGarcía Posadas, Laura 
dc.date.accessioned2024-01-25T13:19:14Z
dc.date.available2024-01-25T13:19:14Z
dc.date.issued2021
dc.identifier.citationPharmaceutics, 2021, vol. 13, n. 8, 1140es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/65031
dc.descriptionProducción Científicaes
dc.description.abstractThe conjunctiva is a complex ocular tissue that provides mechanical, sensory, and immune protection for the ocular surface. It is affected by many diseases through different pathological mechanisms. If a disease is not treated and conjunctival function is not fully restored, the whole ocular surface and, therefore, sight is at risk. Different therapeutic approaches have been proposed, but there are still unsolved conjunctival alterations that require more sophisticated therapeutic options. Advanced therapy medicinal products (ATMPs) comprise a wide range of products that includes cell therapy, tissue engineering, and gene therapy. To the best of our knowledge, there is no commercialized ATMP specifically for conjunctival treatment yet. However, the conjunctiva can be a potential target for ATMPs for different reasons. In this review, we provide an overview of the advances in experimental phases of potential ATMPs that primarily target the conjunctiva. Important advances have been achieved through the techniques of cell therapy and tissue engineering, whereas the use of gene therapy in the conjunctiva is still marginal. Undoubtedly, future research in this field will lead to achieving commercially available ATMPs for the conjunctiva, which may provide better treatments for patients.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectOftalmologíaes
dc.subject.classificationAdvanced therapieses
dc.subject.classificationConjunctivaes
dc.subject.classificationTissue engineeringes
dc.subject.classificationTerapias avanzadases
dc.subject.classificationConjuntivaes
dc.subject.classificationIngeniería Tisulares
dc.titleIs the conjunctiva a potential target for advanced therapy medicinal products?es
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2021 The Authorses
dc.identifier.doi10.3390/pharmaceutics13081140es
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/8/1140es
dc.identifier.publicationfirstpage1140es
dc.identifier.publicationissue8es
dc.identifier.publicationtitlePharmaceuticses
dc.identifier.publicationvolume13es
dc.peerreviewedSIes
dc.description.projectMinisterio de Ciencia e Innovación y Ministerio de Universidades - AEI-FEDER (RTI2018–094071- B-C2)es
dc.identifier.essn1999-4923es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco3201.09 Oftalmologíaes


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem